Form 4: Gevo CCO Kyle James Receives Equity Grant

Gevo, Inc. Chief Commercial Officer Kyle Dean James was granted 133,232 shares of restricted common stock and 153,937 stock options.

Summary

• Chief Commercial Officer Kyle Dean James received an equity grant on May 20, 2026.
• The grant includes 133,232 shares of restricted common stock.
• The grant includes 153,937 stock options with an exercise price of $1.64 per share.
• Both the restricted stock and the options vest in three equal annual installments starting on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through multi-year vesting schedules.

Negatives

• Dilutive impact on existing shareholders due to the issuance of new equity and options.

Risks

• Continued service requirement for vesting creates potential retention risk if the executive departs before the three-year period concludes.

Future Outlook

The equity grants are subject to a three-year vesting schedule, contingent upon the executive's continued service to the company.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice for retaining executive talent in the renewable chemicals and biofuels sector, particularly for companies in growth phases like Gevo.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. energy and technology sectors.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the first installment of restricted stock and options on May 20, 2027.

Key Dates

Keywords

Gevo, GEVO, Insider Trading, Form 4, Executive Compensation, Equity Grant